Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.antiviral.2021.105075 http://scihub22266oqcxt.onion/10.1016/j.antiviral.2021.105075 33872675!8052511!33872675     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Antiviral+Res 2021 ; 190 (ä): 105075 Nephropedia Template TP {{tp|p=33872675|t=2021. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro) |pdf=|usr=}}{{33872675}} gab.com Text Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro) JO: Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=33872675 #FOAvip The emerging SARS-CoV-2 infection is the cause of the global COVID-19 pandemic. To date, there are limited therapeutic options available to fight this disease. Here we examined the inhibitory abilities of two broad-spectrum antiviral natural products chebulagic acid (CHLA) and punicalagin (PUG) against SARS-CoV-2 viral replication. Both CHLA and PUG reduced virus-induced plaque formation in Vero-E6 monolayer at noncytotoxic concentrations, by targeting the enzymatic activity of viral 3-chymotrypsin-like cysteine protease (3CL(pro)) as allosteric regulators. Our study demonstrates the potential use of CHLA and PUG as novel COVID-19 therapies. Twit Text FOAVip Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro) ????Antiviral Res http://www.kidney.de/pget.php?&tw=1&pmid=33872675 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33872675 #FOAvip English Wikipedia <ref>{{Cite pmid|33872675}}</ref> Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro) #MMPMID33872675 Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q Antiviral Res 2021[Jun]; 190 (ä): 105075 PMID33872675show ga The emerging SARS-CoV-2 infection is the cause of the global COVID-19 pandemic. To date, there are limited therapeutic options available to fight this disease. Here we examined the inhibitory abilities of two broad-spectrum antiviral natural products chebulagic acid (CHLA) and punicalagin (PUG) against SARS-CoV-2 viral replication. Both CHLA and PUG reduced virus-induced plaque formation in Vero-E6 monolayer at noncytotoxic concentrations, by targeting the enzymatic activity of viral 3-chymotrypsin-like cysteine protease (3CL(pro)) as allosteric regulators. Our study demonstrates the potential use of CHLA and PUG as novel COVID-19 therapies. |Allosteric Site[MESH] |Animals[MESH] |Antiviral Agents/chemistry/*pharmacology[MESH] |Benzopyrans/chemistry/*pharmacology[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/virology[MESH] |Chlorocebus aethiops[MESH] |Coronavirus 3C Proteases/*antagonists & inhibitors/chemistry/metabolism[MESH] |Drug Discovery[MESH] |Glucosides/chemistry/*pharmacology[MESH] |Hydrolyzable Tannins/*pharmacology[MESH] |Molecular Docking Simulation[MESH] |Protease Inhibitors/pharmacology[MESH] |SARS-CoV-2/*drug effects/metabolism[MESH] |Vero Cells[MESH]Discovery of chebulagic acid and punicalagin as novel allosteric inhib(epmc).pdf DeepDyve Pubget Overpricing